CROHN'S & COLITIS FOUNDATION INC

🔒

Financial Vulnerability Assessment (Tuckman-Chang)

4 risk indicators measuring financial stability and operational resilience

Sign in with your work email to view Tuckman-Chang indicators

Financial Trends

Organization Details

Formation Year

1967

Legal Domicile

Principal Officer

MICHAEL OSSO

Phone

8009322423

Tax Period

2024-01-01 to 2024-12-31

CROHN'S & COLITIS FOUNDATION INC, founded in 1967, is a mid-sized nonprofit in the Diseases & Disorders sector that reported $85.2M in total revenue in fiscal year 2024.

Mission

FOR OVER FIVE DECADES, THE CROHN'S & COLITIS FOUNDATION ("THE FOUNDATION") HAS BEEN DEDICATED TO ITS MISSION OF FINDING A CURE FOR CROHN'S DISEASE AND ULCERATIVE COLITIS AND IMPROVING THE QUALITY OF LIFE OF CHILDREN AND ADULTS AFFECTED BY THESE DISEASES. (SEE SCHED O)THE FOUNDATION HAS DEFINED ITSELF BY SPONSORING THE BEST AND BRIGHTEST RESEARCHERS RESULTING IN GROUNDBREAKING STUDIES AND RESEARCH INITIATIVES TO ADVANCE THE UNDERSTANDING AND TREATMENT OF INFLAMMATORY BOWEL DISEASES ("IBD").

Program Service Accomplishments

Program 1

Expenses: $34,993,675 Revenue: $8,790,214

SINCE ITS INCEPTION, THE CROHN'S & COLITIS FOUNDATION HAS PROVIDED MORE THAN $500 MILLION FOR RESEARCH ON THE TREATMENT AND CURES OF IBD. THE FOUNDATION FUNDS A SET OF PRIORITY RESEARCH INITIATIVES: MULTI-INSTITUTIONAL, MULTI-DISCIPLINARY, COLLABORATIVE RESEARCH PROJECTS TARGETING AREAS OF SCIENCE WITH A HIGH PROBABILITY OF ADVANCING TREATMENT. THE FOUNDATION HAS DEFINED ITSELF BY SPONSORING THE BEST AND BRIGHTEST RESEARCHERS RESULTING IN GROUNDBREAKING STUDIES AND RESEARCH INITIATIVES TO ADVANCE THE UNDERSTANDING AND TREATMENT OF INFLAMMATORY BOWEL DISEASES ("IBD"). (CONTINUED IN SCHEDULE O)THE FOUNDATION'S RESEARCH PORTFOLIO IS A COMBINATION OF BASIC, TRANSLATIONAL, AND CLINICAL RESEARCH. DESIGNED TO CUT YEARS OFF THE RESEARCH PROCESS, IBD PLEXUS, THE FOUNDATION'S INNOVATIVE RESEARCH PLATFORM, IS THE SINGLE LARGEST IBD DATABASE IN THE US AND THE MOST COMPREHENSIVE IBD DATABASE IN THE WORLD. IT CURRENTLY PROVIDES RESEARCHERS WITH DATA FROM OVER 30,000 PATIENTS, INCLUDING 250,000 BIOSAMPLES (BLOOD, STOOL, AND INTESTINAL TISSUE).THE FOUNDATION LEADS THE WAY IN NEW, CRITICALLY IMPORTANT AREAS OF IBD RESEARCH, AND ACCELERATING NOVEL THERAPIES AND INNOVATIVE PRODUCTS THAT ADDRESS UNMET PATIENT NEEDS. IN 2020, THE FOUNDATION LAUNCHED THE MOST EXTENSIVE IBD-FOCUSED PRECISION NUTRITION EFFORT, TO BETTER UNDERSTAND THE DIRECT IMPACT THAT FOOD MAY HAVE IN THE MANAGEMENT OF IBD AND ON PATIENT QUALITY OF LIFE. THE FOUNDATION ALSO LAUNCHED THE SURGICAL RESEARCH NETWORK, OUR FIRST-EVER COORDINATED-FUNDING EFFORT TO STUDY SURGICAL OUTCOMES IN IBD, WITH OVER 50 CENTERS PARTICIPATING.

Program 2

Expenses: $32,995,237 Revenue: $322,060

THE CROHN'S & COLITIS FOUNDATION PROVIDES INFORMATION AND EDUCATION FOR THE MILLIONS OF INDIVIDUALS WITH IBD AND THEIR LOVED ONES THROUGH A VARIETY OF CHANNELS AT THE NATIONAL AND LOCAL LEVEL...

THE CROHN'S & COLITIS FOUNDATION PROVIDES INFORMATION AND EDUCATION FOR THE MILLIONS OF INDIVIDUALS WITH IBD AND THEIR LOVED ONES THROUGH A VARIETY OF CHANNELS AT THE NATIONAL AND LOCAL LEVEL INCLUDING IN-PERSON AND WEB-BASED EDUCATION, SUPPORT PROGRAMS INCLUDING PEDIATRIC AND ADULT FOCUS INITIATIVES, IBD HELP CENTER ANSWERING QUESTIONS AND PROVDING SUPPORT FOR THOSE WITH IBD, AND NUMEROUS PRINTED MATERIALS PROVIDINGACCURATE AND UP-TO-DATE INFORMATION. IN A RECENT IMPACT STUDY, OVER 85% OF PATIENTS CONNECTED WITH THE FOUNDATION STATED THAT THE FOUNDATION HAS HAD A POSITIVE IMPACT ON THEIR IBD JOURNEY. THESE PATIENTS ALSO REPORTED BETTER SYMPTOM CONTROL THAN NON-FOUNDATION CONNECTED PATIENTS. (CONTINUED IN SCHEDULE O)THE FOUNDATION ALSO OFFERS PROFESSIONAL EDUCATION THROUGH OUR TWO SCIENTIFIC JOURNALS, INFLAMMATORY BOWEL DISEASES AND CROHN'S & COLITIS 360, AS WELL AS THROUGH HEALTH PROFESSIONAL EDUCATION PROGRAMS BOTH IN-PERSON AND WEB-BASED. IN ADDITION THE FOUNDATION HOSTS THE ANNUAL CROHN'S & COLITIS CONGRESS CONFERENCE. IN THE PAST YEAR, THE FOUNDATION LAUNCHED A PUBLIC SERVICE AWARENESS CAMPAIGN TO INCREASE FAMILIARITY OF IBD WITH THE GENERAL PUBLIC AND REDUCE THE STIGMA FOR THOSE INDIVIDUALS WITH IBD.

🔒

Trantor Score

Financial Health Score (300–850) · Liquidity · Solvency · Sustainability · Efficiency

Sign in to view Trantor Score and financial metrics

Liquidity (40%) • Solvency (30%) • Sustainability (20%) • Efficiency (10%)

Financial Overview (2024)

Revenue Breakdown

Contributions & Grants $73,888,862

Program Service Revenue $9,112,274

Investment Income $1,327,009

Other Revenue $854,203

TOTAL REVENUE $85,182,348

Expense Breakdown

Grants Paid $23,680,607

Salaries & Benefits $39,220,848

Fundraising Expenses $6,004,020

Program Expenses $67,988,912

Other Expenses $20,268,743

TOTAL EXPENSES $83,504,823

Year-over-Year Comparison

	2024	2023	Change
Revenue	$85,182,348	$81,765,248	+0.0%
Expenses	$83,504,823	$86,537,979	0.0%
Net Income	$1,677,525	$-4,772,731	-1.4%

Key Indicators

✓ Grants to Organizations ✗ Grants to Individuals ✓ Lobbying ✗ Political Activity ✓ Foreign Activities ✗ Donor Advised Fund ✓ Schedule B Required

🔒

Financial Health Indicators

Comprehensive financial analysis: Altman Z-Score, liquidity, solvency, sustainability, efficiency, and growth metrics

Financial Distress Indicator

Liquidity & Cash Position

Sign in to view all financial metrics

Altman Z-Score • Liquidity Ratios • Solvency Analysis • Growth Indicators • Efficiency Metrics

Governance

Voting Members

Independent Members

Employees

372

Volunteers

6005

Governance Policies

✓ Conflict of Interest Policy

✓ Whistleblower Policy

✓ Document Retention Policy

Special Practices & Reported Activities

✗ Operated a School

✗ Operated a Hospital

✗ Provided First Class Travel

✗ Reported Conflict of Interest

✗ Reported Asset Diversion

✗ Excess Benefit Transaction

✗ Made Political Expenditures

✓ Engaged in Lobbying

✗ Operated Donor Advised Fund

✗ Maintained Art Collections

✗ Filed Form 720

Compensation of Officers, Directors & Key Employees

Total Officers

$1,100,310

Total Directors

$762,198

Key Employees

$1,908,552

Highest Compensated

reported

Name	Title	Hours/Week	Role	Reportable Comp	Other Comp	Total
MICHAEL OSSO	PRESIDENT/CEO(NON-VOTING)	35.00	Officer Director	$604,255	$157,943	$762,198
DANIEL STONE	TREASURER	1.00	Officer Director	$0	$0	$0
JODI YELLEN	SECRETARY (THRU 03/2024)	1.00	Officer Director	$0	$0	$0
JEFFREY MITTLEMAN	SECRETARY (AS OF 03/2024)	1.00	Officer Director	$0	$0	$0
BRENT POLK MD	CHAIRMAN (THRU 03/2024)	1.00	Officer Director	$0	$0	$0
AMBER BACKHAUS	CHAIRMAN (AS OF 03/2024)	1.00	Officer Director	$0	$0	$0
RHONDA BOLDING	TRUSTEE	1.00	Director	$0	$0	$0
NOEL BROWN	TRUSTEE (AS OF 03/2024)	1.00	Director	$0	$0	$0
JOHN CAPODILUNO	TRUSTEE	1.00	Director	$0	$0	$0
CHASE CARPENTER	TRUSTEE	1.00	Director	$0	$0	$0
ROCIO CASTRILLON	TRUSTEE (AS OF 03/2024)	1.00	Director	$0	$0	$0
DEBORAH CRAWFORD	TRUSTEE	1.00	Director	$0	$0	$0
TOLULOPE FALAIYE MD	TRUSTEE	1.00	Director	$0	$0	$0
BECKY FLAHERTY	TRUSTEE (AS OF 03/2024)	1.00	Director	$0	$0	$0
ALEX FUNDERBURG	TRUSTEE (THRU 03/2024)	1.00	Director	$0	$0	$0
CHERYL GUERIN	TRUSTEE	1.00	Director	$0	$0	$0
KEVIN HARLEN	TRUSTEE	1.00	Director	$0	$0	$0
PETER HIGGINS MD PHD MSC	NSAC CHAIR ELECT	1.00	Officer Director	$0	$0	$0
KELLY ISSOKSON MSRDCNSC	TRUSTEE	1.00	Director	$0	$0	$0
SEAN KELLEY	TRUSTEE (THRU 03/2024)	1.00	Director	$0	$0	$0
SANDRA KIM MD	TRUSTEE (AS OF 03/2024)	1.00	Director	$0	$0	$0
MICHELE KISSOUS-HUNT	TRUSTEE (THRU 03/2024)	1.00	Director	$0	$0	$0
ANNETTE MARTINEZ	TRUSTEE	1.00	Director	$0	$0	$0
AUDRA MILLER	TRUSTEE	1.00	Director	$0	$0	$0
JOE MONK	TRUSTEE (THRU 03/2024)	1.00	Director	$0	$0	$0
MARK MURRAY PHD	TRUSTEE (THRU 03/2024)	1.00	Director	$0	$0	$0
ARMIN RAHMANIAN	TRUSTEE	1.00	Director	$0	$0	$0
MEGAN RIEHL PSYD	TRUSTEE (AS OF 03/2024)	1.00	Director	$0	$0	$0
JONATHAN ROSE	TRUSTEE (AS OF 07/2024)	1.00	Director	$0	$0	$0
DAVID RUBIN MD	TRUSTEE	1.00	Director	$0	$0	$0
FRANK RUSSOMANO	TRUSTEE (THRU 03/2024)	1.00	Director	$0	$0	$0
LORI SIEGEL RABINOWITZ	TRUSTEE	1.00	Director	$0	$0	$0
ANDREW STERN	TRUSTEE (AS OF 03/2024)	1.00	Director	$0	$0	$0
NICHOLAS UZL	TRUSTEE (THRU 06/2024)	1.00	Director	$0	$0	$0
TROY VOLLERTSEN	TRUSTEE	1.00	Director	$0	$0	$0
DOUGLAS WOLF MD	TRUSTEE (AS OF 03/2024)	1.00	Director	$0	$0	$0
SHARON LUNGRIN	CHIEF OP. OFF./CHIEF FIN.	35.00	Officer	$267,379	$70,733	$338,112
ALAN MOSS	CHIEF SCIENTIFIC OFFICER	35.00	Key Emp	$450,466	$13,858	$464,324
ROHIT SURI	CHIEF TECHNOLOGY OFFICER	35.00	Key Emp	$304,578	$78,567	$383,145
ALLISON COFFEY	CHIEF DEVELOPMENT OFFICER	35.00	Key Emp	$273,205	$22,804	$296,009
CHRIS FIDYK	EVP, BUSINESS DEVELOPMENT	35.00	Key Emp	$213,952	$4,083	$218,035
CHRISTY DESANTIS	CHIEF MKTNG. & COMM. OFFCR.	35.00	Key Emp	$256,701	$26,914	$283,615
LAURA WINGATE	CHIEF EDU. SUPP. & ADVOC. OFFICER	35.00	Key Emp	$219,544	$43,880	$263,424
SARAH WEAVER	VP, CLINICAL QUALITY & INNOVATION	35.00	Highest	$206,702	$16,415	$223,117
ANGELA DOBES	VICE PRESIDENT, IBD PLEXUS	35.00	Highest	$259,396	$17,475	$276,871
MARISA MAYER	CHIEF LEGAL OFFICER	35.00	Highest	$259,396	$76,835	$336,231
LEANA PATEL	VP, PEOPLE & CULTURE	35.00	Highest	$202,086	$26,800	$228,886
JACK MATARASSO	SVP, DIGITAL MARKETING	35.00	Highest	$202,684	$15,941	$218,625

Note: Compensation data is self-reported by the organization on their Form 990. "Reportable Comp" includes salary, bonuses, and other reportable compensation from the organization and related organizations. "Other Comp" includes benefits, deferred compensation, and non-taxable benefits.

Historical Data

Year	Revenue	Expenses	Assets	Net Income
2024	No data	No data	No data	No data
2024	$85,182,348	$83,504,823	$50,647,406	$1,677,525
2023	$81,765,248	$86,537,979	$54,000,124	$-4,772,731
2022	$81,491,223	$82,569,900	$57,441,645	$-1,078,677
2021	$78,027,022	$78,323,556	$57,664,028	$-296,534
2020	$76,220,042	$75,670,117	$55,619,176	$549,925
2019	$73,925,250	$75,723,530	$45,274,249	$-1,798,280
2018	$73,887,231	$73,648,875	$46,583,088	$238,356